188 related articles for article (PubMed ID: 27102929)
21. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children.
Dai WJ; Zhang RR; Yang XC; Yuan YF
Eur Rev Med Pharmacol Sci; 2015 Jul; 19(13):2379-83. PubMed ID: 26214772
[TBL] [Abstract][Full Text] [Related]
23. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases.
Schiavotto C; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):22-8. PubMed ID: 8039754
[TBL] [Abstract][Full Text] [Related]
24. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M;
Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672
[TBL] [Abstract][Full Text] [Related]
26. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Oved JH; Lee CSY; Bussel JB
J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
30. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.
Chugh S; Darvish-Kazem S; Lim W; Crowther MA; Ghanima W; Wang G; Heddle NM; Kelton JG; Arnold DM
Lancet Haematol; 2015 Feb; 2(2):e75-81. PubMed ID: 26687612
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis.
Wang J; Li Y; Wang C; Zhang Y; Gao C; Lang H; Chen X
Biomed Res Int; 2018; 2018():1316096. PubMed ID: 30648105
[No Abstract] [Full Text] [Related]
33. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
[TBL] [Abstract][Full Text] [Related]
34. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
[TBL] [Abstract][Full Text] [Related]
35. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G
Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
[TBL] [Abstract][Full Text] [Related]
37. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.
Cheng Y; Wong RS; Soo YO; Chui CH; Lau FY; Chan NP; Wong WS; Cheng G
N Engl J Med; 2003 Aug; 349(9):831-6. PubMed ID: 12944568
[TBL] [Abstract][Full Text] [Related]
38. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
39. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.
Chapin J; Lee CS; Zhang H; Zehnder JL; Bussel JB
Am J Hematol; 2016 Sep; 91(9):907-11. PubMed ID: 27220625
[TBL] [Abstract][Full Text] [Related]
40. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.
Pamuk GE; Pamuk ON; Başlar Z; Ongören S; Soysal T; Ferhanoğlu B; Aydin Y; Ulkü B; Aktuğlu G; Akman N
Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
